Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
← catalyst calendarSponsored by Candel Therapeutics, Inc. (industry) · CADL — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
187actual
Sites
23
Countries
Mexico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2016 | not stated | When the study began enrolling |
| Primary completion | Nov 2024 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2016-05-11 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Biological: aglatimagene besadenovec — also filed as AdV-tk, CAN-2409
- Biological: placebo
- Drug: valacyclovir
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Baseline to study completion, approximately 5 years
Permalink · CADL's whole pipeline · Catalyst calendar · Every registered study · What changed